METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION

Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION explained in plain language.

Never miss a new study

Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION trials appear

Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New Two-Pronged attack on advanced prostate cancer

Disease control Ongoing

This study is testing whether combining two drugs, olaparib and cediranib, is more effective than using olaparib alone for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread. The trial aims to see if the drug combo can better …

Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION

Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION trials appear

New Two-Pronged attack on advanced prostate cancer